{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:10:36Z","timestamp":1792041036778,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bmc.2024.117657","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T02:33:52Z","timestamp":1709001232000},"page":"117657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8402-6461","authenticated-orcid":false,"given":"Dapeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renshuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-8226","authenticated-orcid":false,"given":"Shiyong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117657_b0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody\u2013drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117657_b0010","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-14-1078","article-title":"AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma","volume":"14","author":"Hamblett","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2024.117657_b0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrclinonc.2017.95","article-title":"Antibody\u2013drug conjugates in glioblastoma therapy: the right drugs to the right cells","volume":"14","author":"Gan","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117657_b0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2020.08.016","article-title":"Nano-therapeutics for modulating the tumour microenvironment: design, development, and clinical translation","volume":"327","author":"Adityan","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2024.117657_b0025","article-title":"Epidermal growth factor receptor targeting and challenges in glioblastoma","volume":"nov319","author":"Thorne","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bmc.2024.117657_b0030","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2024.117657_b0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/1061186X.2022.2152819","article-title":"Engineered anti-EGFRvIII targeted exosomes induce apoptosis in glioblastoma multiforme","volume":"31","author":"Rahmani","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.bmc.2024.117657_b0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1535-7163.MCT-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2024.117657_b0045","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","article-title":"Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy","volume":"72","author":"Gan","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2024.117657_b0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2967\/jnumed.120.253146","article-title":"A phase 1 and biodistribution study of ABT-806i, an 111In-radiolabeled conjugate of the tumor-specific anti-EGFR antibody ABT-806","volume":"62","author":"Gan","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmc.2024.117657_b0055","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","article-title":"Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody","volume":"14","author":"Reilly","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2024.117657_b0060","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1158\/1078-0432.CCR-04-2653","article-title":"Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity","volume":"11","author":"Perera","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2024.117657_b0065","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/j.1582-4934.2009.00783.x","article-title":"Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-\u03baB and initiates tumour vascular normalization","volume":"13","author":"Gan","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bmc.2024.117657_b0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jcph.1418","article-title":"An integrated population pharmacokinetic model versus individual models of depatuxizumab mafodotin, an anti-EGFR antibody drug conjugate, patients with solid tumors likely to overexpress EGFR","volume":"59","author":"Mittapalli","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2024.117657_b0075","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/j.1349-7006.2008.00945.x","article-title":"Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III","volume":"99","author":"Fukai","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmc.2024.117657_b0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.radonc.2009.06.021","article-title":"Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells","volume":"92","author":"Jutten","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bmc.2024.117657_b0085","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/neuonc\/noac204","article-title":"EGFR, the lazarus target for precision oncology in glioblastoma","volume":"24","author":"Lin","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bmc.2024.117657_b0090","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdac130","article-title":"Convection enhanced delivery of EGFR targeting antibody-drug conjugates serclutamab talirine and depatux-M in glioblastoma patient-derived xenografts","volume":"4","author":"Porath","year":"2022","journal-title":"Neuro-Oncology Advances"},{"key":"10.1016\/j.bmc.2024.117657_b0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3171\/jns.1991.75.1.0097","article-title":"Transforming growth factor- \u03b1, epidermal growth factor receptor, and proliferating potential in benign and malignant gliomas","volume":"75","author":"Maruno","year":"1991","journal-title":"J Neurosurg"},{"key":"10.1016\/j.bmc.2024.117657_b0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jcb.240580206","article-title":"Cell cycle and apoptosis: common pathways to life and death","volume":"58","author":"King","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmc.2024.117657_b0105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2018.04.035","article-title":"A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery","volume":"279","author":"Ruan","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2024.117657_b0110","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1593\/neo.08928","article-title":"Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model","volume":"10","author":"Mathieu","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.bmc.2024.117657_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmc.2024.117657_b0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","article-title":"Recent advances in the molecular understanding of glioblastoma","volume":"108","author":"Bleeker","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bmc.2024.117657_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-020-01724-6","article-title":"Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas","volume":"39","author":"Mudassar","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bmc.2024.117657_b0130","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmc.2024.117657_b0135","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"key":"10.1016\/j.bmc.2024.117657_b0140","first-page":"696","article-title":"The blood\u2013tumour barrier in cancer biology and therapy, nature reviews","volume":"18","author":"Steeg","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117657_b0145","series-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","author":"Mair","year":"2023"},{"key":"10.1016\/j.bmc.2024.117657_b0150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/sj.cdd.4401724","article-title":"Classification of cell death: recommendations of the nomenclature committee on cell death","volume":"12","author":"Kroemer","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bmc.2024.117657_b0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody\u2013drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bmc.2024.117657_b0160","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1101\/gad.287524.116","article-title":"Recent insights into the function of autophagy in cancer","volume":"30","author":"Amaravadi","year":"2016","journal-title":"Genes Dev"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:24:48Z","timestamp":1760837088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"alternative-id":["S0968089624000713"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117657","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117657"}}